Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04847921 · ClinicalTrials.gov registry record · Phase 2
Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient Transition
A Phase 2 study, sponsored by University of Colorado, Denver.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT04847921 is a Phase 2 study that was terminated before completion, run by University of Colorado, Denver. The registered enrollment target is 11 participants.
The verdict
NCT04847921, a Phase 2 study, was terminated before completion, sponsored by University of Colorado, Denver.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
The Investigators aim to study the outcomes of serious infections due to vancomycin susceptible infections in gram-positive organisms susceptible to vancomycin in people who use drugs (PWUD). The Investigators hypothesize, that a simplified 2-dose dalbavancin regimen, will improve compliance with antimicrobial therapy and that it may facilitate engagement in the treatment of the underlying substance use disorder, and particularly injection drug use - often the true etiology behind these severe infections.
Interventions
- DRUG Dalbavancin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2021-04-30 |
| Est. Completion | 2023-10-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04847921
The ClinicalTrials.gov registry entry for NCT04847921 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dalbavancin is the first listed.
NCT04847921 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04847921 about?
NCT04847921 is a clinical study titled "Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient Transition". The Investigators aim to study the outcomes of serious infections due to vancomycin susceptible infections in gram-positive organisms susceptible to vancomycin in people who use drugs (PWUD). The Investigators hypothesize, that a simplified 2-dose dalbavancin regimen, will improve compliance with an...
What is the current status of trial NCT04847921?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2021-04-30. Estimated completion is 2023-10-05.
What interventions are being tested in trial NCT04847921?
The interventions under investigation include: Dalbavancin (DRUG).
Who is sponsoring clinical trial NCT04847921?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.